Immunome, Inc. (IMNM) is scheduled to report topline Phase 3 results of its lead drug candidate, Varegacestat, in desmoid tumors, dubbed RINGSIDE trial, today.
Desmoid tumors are rare, locally aggressive soft tissue neoplasms that, while non-metastatic, can cause significant morbidity. Current treatment options remain limited, highlighting the need for targeted therapies.
Varegacestat is designed to inhibit gamma secretase, a key enzyme implicated in the pathogenesis of desmoid tumors.
The RINGSIDE, which is a placebo-controlled phase 3 trial, has enrolled 156 patients aged 12 and older with progressive desmoid tumors.
Beyond Varegacestat, Immunome's pipeline includes multiple first-in-class targeted oncology programs:
• IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) incorporating Immunome's proprietary HC74 payload, is in Phase 1 with initial lymphoma data expected in 2026.• IM-3050, a FAP-targeted radiotherapy, recently received IND clearance, and a Phase 1 study is planned for early 2026.• HC74 payload, a novel topoisomerase I inhibitor designed to overcome multi-drug resistance. Preclinical data demonstrated efficacy in colorectal cancer refractory to trastuzumab-DXd, NSCLC with heterogeneous target expression, and other resistant tumor models.• The company is also advancing a portfolio of HC74-based ADCs - IM-1617, IM-1340, and IM-1335 against undisclosed solid tumor targets, which are currently progressing towards IND submission.
The company ended September 30, 2025, with cash of $272.6 million, providing runway into 2027.
IMNM has traded in the range of $5.15 to $20.80 over the past year. The stock closed Friday's trading at $19.57, up 0.41%, and rose further in the overnight trading to $20.49, up 4.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.